·Week of August 24-28, 2026

Clinical Trials Brief | August 31, 2026

This week: individualised mRNA cancer vaccines posting a Phase 3 win and a Phase 2 survival imbalance nine days apart, FDA extending the deramiocel review after a post-advisory-committee data package, the four-week countdown to CTIS's new annual safety report module, a new FDA clinical hold on RGX-121 after spinal MRI findings, and CARDIO-TTRansform's full results at ESC confirming the topline miss.

Individualised mRNA cancer vaccines post a Phase 3 win and a Phase 2 survival imbalance nine days apart

What changed

On August 28, 2026, BioNTech announced that it would terminate the Phase 2 BNT122-01 trial of autogene cevumeran, an individualised mRNA cancer immunotherapy developed with Genentech, as adjuvant monotherapy in ctDNA-positive, resected high-risk stage II or stage III colorectal cancer. The independent DSMB identified a numerical imbalance in overall survival between arms and concluded that continuing was unlikely to change the efficacy outcome. A Genentech spokesperson confirmed to Fierce Biotech that there were more deaths in the vaccine arm. The trial had already crossed a futility boundary in October 2025 but continued because the data were immature. BioNTech reported no new safety signals and said the Phase 2 IMcode003 trial in pancreatic cancer, which combines the vaccine with a checkpoint inhibitor and chemotherapy, continues. Nine days earlier, on August 19, Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab in 1,137 patients with resected stage IIB-IV melanoma met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival versus pembrolizumab alone.

Why it matters

The contrast is about context, not platform. The positive result came in combination with a PD-1 inhibitor in melanoma, a highly immunogenic tumour. The negative result came with the vaccine alone, compared with watchful waiting, in colorectal cancer, a tumour type that has historically responded poorly to immunotherapy. BioNTech's own statement points to the challenge of immune-suppressive tumour microenvironments. A survival imbalance is more concerning than simple futility, but BioNTech has not disclosed its size or significance. In my reading, the full BNT122-01 data, including patient selection and causes of death, are essential before drawing class conclusions.

Takeaway

For DSMB practice, BNT122-01 is a useful case: crossing a futility boundary on immature data led to continuation, and later data showed an imbalance. DSMB charters should spell out how to act when futility is crossed early but uncertainty remains. For individualised vaccine programmes, combination with checkpoint inhibition now looks like the evidence-based starting point.

FDA extends the deramiocel review to November after a post-advisory-committee data package and a narrower indication

What changed

On August 24, 2026, Capricor announced that FDA had extended the PDUFA date for deramiocel, its cell therapy for Duchenne muscular dystrophy, from August 22 to November 22, 2026. After the July 29 advisory committee voted 9-3 that the evidence did not show effectiveness in DMD cardiomyopathy, Capricor submitted a BLA amendment with 24-month open-label extension data from the Phase 3 HOPE-3 trial and additional robustness analyses. It asked FDA to review the existing and new data in support of a refined indication focused on upper limb function, which Capricor describes as HOPE-3's primary endpoint. CBER accepted the amendment, citing the significant unmet need in DMD, and classified it as a major amendment, which adds three months to the review. FDA's July briefing documents had stated that HOPE-3 did not meet its prespecified primary and secondary endpoints under the analysis FDA considered applicable.

Why it matters

This brief covered the deramiocel advisory committee on August 3 as a case study in statistical analysis plan governance. The extension does not resolve that dispute. It changes the question by narrowing the indication to the endpoint where Capricor believes the evidence is strongest, and by adding longer, uncontrolled follow-up. The open-label extension data cannot replace a controlled comparison, but they may support durability. How FDA weighs a narrower indication, a disputed analysis plan and uncontrolled long-term data will be closely watched in rare-disease development.

Takeaway

Post-advisory-committee amendments are a legitimate route, but they reset the review clock and do not erase the original analysis-plan questions. Rare-disease sponsors should align the primary endpoint, analysis plan and proposed indication with FDA before unblinding, so the indication does not have to be reshaped after an adverse panel vote.

Sources

This item is grounded in Capricor's SEC filing and press release of August 24, 2026 and reporting by NeurologyLive and Global Genes RARE Daily.

Four weeks to go: CTIS's new annual safety report module goes live on September 28, replacing the current ASR route

What changed

EMA published sponsor and Member State guidance for the new CTIS safety module for annual safety reports (ASRs) on July 31, 2026, and opened a training environment the same day. The go-live date is now four weeks away. According to the Norwegian Medical Products Agency, the module goes live on Monday, September 28, 2026, followed by a two-month transition ending on November 30. Ongoing ASRs will be finalised in the current system, but from go-live all new ASRs must be submitted and managed in the new module, and submission through the current route will no longer be possible. Access to finalised ASRs in the current system ends after the transition. EMA's CTIS Simplification Task Force designed the module to simplify ASR business rules and allow selection of a safety assessing Member State.

Why it matters

ASRs (DSURs in ICH terms) are a recurring compliance obligation for every sponsor with EU trials, and changes to the submission route are where missed deadlines and rejected submissions happen. The loss of access to finalised ASRs in the old system after November 30 is an easy detail to miss, with consequences for inspection readiness: sponsors need their own complete copies of what was submitted and when, rather than relying on CTIS as the archive.

Takeaway

Pharmacovigilance and regulatory operations teams should use the training environment before September 28, update SOPs and work instructions for ASR submission and responses to requests for information, and download and file all ASRs and related correspondence from the current system into the TMF before access ends on November 30.

Sources

This item is grounded in EMA's sponsor and Member State guidance on the new CTIS safety module (published July 31, 2026), the Norwegian Medical Products Agency notice, and EMA's CTIS Simplification Task Force document.

FDA places RGX-121 on clinical hold after expanded MRI monitoring finds spinal lesions years after dosing

What changed

On August 24, 2026, REGENXBIO announced that FDA had placed the Phase 1/2/3 CAMPSIITE trial of RGX-121 (clemidsogene lanparvovec), its gene therapy for mucopolysaccharidosis type II (Hunter syndrome), on clinical hold. An expanded MRI monitoring plan, introduced a few months earlier after a separate hold on the related RGX-111 programme and adding spine imaging to brain MRI, found a small nodule or small cystic mass in the spine of five participants who received intracisternal or intraventricular RGX-121 about three to six years earlier. The participants are asymptomatic, investigators consider the findings non-serious, and radiologists believe they are likely benign. No abnormalities were seen on brain MRI. There is no clinical or pathological evidence on the nature or cause of the findings. Because spine MRI is not routine in MPS care or trials, their background prevalence in this population is unknown. REGENXBIO does not expect to resubmit its BLA in the near term; according to Becker's Spine Review, FDA had issued a complete response letter in February citing gaps in the evidence of effectiveness.

Why it matters

This hold resulted from the sponsor looking harder, not from a clinical event. Enhanced surveillance found something nobody had looked for before, and there is no baseline to say whether it is drug-related or part of the disease. For CNS-delivered AAV gene therapies, that creates an uncomfortable question: findings may emerge years after a one-time dose, and without natural-history imaging data they are hard to interpret. Regulators are likely to treat new imaging findings conservatively until causation is understood.

Takeaway

For long-term follow-up of gene therapy trials, define imaging surveillance (what, where, how often) in the protocol from the start, and where possible collect matched imaging in natural-history or untreated cohorts so that later findings can be interpreted. Expedited safety reporting of unexpected imaging findings, as REGENXBIO did, remains the right call even when participants are asymptomatic.

CARDIO-TTRansform's full results at ESC 2026 confirm the topline miss, despite lower TTR levels

What changed

On August 28, 2026, full results from the Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloid cardiomyopathy were presented in a Hot Line session at the European Society of Cardiology Congress in Munich. According to HCPLive, the data showed no significant reduction in cardiovascular mortality or recurrent cardiovascular events versus placebo, confirming the topline result AstraZeneca and Ionis announced on July 9. Presenting author Mathew Maurer of Columbia University noted that eplontersen reduced circulating serum TTR in what is the largest ATTR-CM trial to date, which enrolled 1,432 participants, but that this did not translate into a significant reduction in the primary endpoint in the overall population.

Why it matters

This brief covered the topline miss on July 13 as a lesson about testing an add-on against an evolving standard of care: most participants ended up on a TTR stabiliser. The full presentation adds the biomarker-outcome gap, with TTR lowered but outcomes not improved, the same pattern seen in Novo Nordisk's ZEUS trial with IL-6 inhibition at the end of July. Two large outcome trials in a single summer, each confirming target engagement without clinical benefit, are a strong reminder that biomarker reduction alone does not establish efficacy.

Takeaway

When a target-engagement biomarker is used to justify an outcomes trial, sponsors should prespecify how they will interpret biomarker success with clinical failure, including subgroup analyses by background therapy. The peer-reviewed publication will be the basis for any further analysis of the stabiliser-free (monotherapy) subgroup that commentators highlighted after the topline.

Sources

This item is grounded in HCPLive reporting of the ESC 2026 Hot Line presentation and the Ionis announcement of July 9, 2026.

Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated.